In this article, discuss the methods of assuring patient adoption during biosimilar development and commercialization.
The PANSS assessment is the cornerstone of efficacy analysis for a majority of clinical trials. Raters play a significant role in obtaining this data. This is typically site raters, but the use of remote raters is increasing. A multitude of studies fail to demonstrate change in symptoms based on PANSS scoring. It is critical that sources of variability among raters is minimized in order to ensure that PANSS assessments are accurate.
This poster is written by Bethanne Friedmann, PsyD, Henry Riordan, PhD, Erin Kornsey, MS, Evan Braxton, Michael F. Murphy, MD, PhD, and Neal R. Cutler, MD.
Central Nervous System (CNS)
Michael F. Murphy, Chief Medical and Scientific Officer at Worldwide Clinical Trials, states that factors related to medication adherence and cost suggest that antipsychotic medication use can improve outcomes in selected patients.
Read more with this article that was taken from American Health & Drug Benefits, Volume 9, Issue 7, in October 2016.
Identifying risk has consistently remained a top priority in clinical trials – especially in transformative therapies. With changes to study development, safety, value and innovation, the widespread utilisation of registries could mean a transformational shift across the whole trial landscape.